This poster presents key insights into global public and philanthropic investment in antibacterial research and development between 2017 and 2023, based on our recently published Lancet Microbe paper.
๐๐ก๐๐ญ ๐๐ข๐ ๐ฐ๐ ๐๐ข๐ง๐?
ยท Investment peaked in 2020 and has since fallen by 18%
ยท $2.51 billion was invested by 130 funders, with funding highly concentrated among a few major players
ยท Early-research funding has declined, while clinical development remains relatively stable
ยท Funding broadly aligns with WHO priority pathogens, though some gaps remain
ยท Traditional approaches dominate, while many non-traditional strategies, like phages, peptides etc., struggle to translate
๐๐ก๐ฒ ๐ญ๐ก๐ข๐ฌ ๐ฆ๐๐ญ๐ญ๐๐ซ๐ฌ
As private investment continues to shrink, antibacterial innovation increasingly relies on public funding, philanthropy, and partnerships
Initiatives such as Global Antibiotic R&D Partnership (GARDP) and CARB-X are essential โ but they alone cannot sustain the system
๐๐ฎ๐ซ ๐ญ๐๐ค๐-๐ก๐จ๐ฆ๐ ๐ฆ๐๐ฌ๐ฌ๐๐ ๐
Sustained investment is necessary, but stronger strategic alignment across funders, sectors, and R&D stages is essential to deliver new antibacterial medicines that meet priority public health needs
This work is the result of a close collaboration between Global Antibiotic R&D Partnership (GARDP) and the Global AMR R&D Hub.
